Alan Seth  Krasner net worth and biography

Alan Krasner Biography and Net Worth

Chief Endocrinologist of Crinetics Pharmaceuticals

Dr. Krasner serves as our Chief Endocrinologist and joined as our Chief Medical Officer in June 2018. Prior to Crinetics, he was a Senior Medical Director at Shire Pharmaceuticals where he served as Global Development Lead for Natpara®, the first recombinant human intact parathyroid hormone treatment for hypoparathyroidism. Prior to Shire, Dr. Krasner worked at Biodel and Pfizer conducting clinical research at various stages of development in diabetes and obesity.

He obtained both his undergraduate and M.D. degrees from Northwestern University and received his clinical training in Internal Medicine and Endocrinology at Johns Hopkins University.

What is Alan Seth Krasner's net worth?

The estimated net worth of Alan Seth Krasner is at least $2.32 million as of October 17th, 2023. Dr. Krasner owns 43,210 shares of Crinetics Pharmaceuticals stock worth more than $2,316,056 as of December 21st. This net worth approximation does not reflect any other investments that Dr. Krasner may own. Additionally, Dr. Krasner receives an annual salary of $653,920.00 as Chief Endocrinologist at Crinetics Pharmaceuticals. Learn More about Alan Seth Krasner's net worth.

How old is Alan Seth Krasner?

Dr. Krasner is currently 61 years old. There are 4 older executives and no younger executives at Crinetics Pharmaceuticals. Learn More on Alan Seth Krasner's age.

What is Alan Seth Krasner's salary?

As the Chief Endocrinologist of Crinetics Pharmaceuticals, Inc., Dr. Krasner earns $653,920.00 per year. There are 3 executives that earn more than Dr. Krasner. The highest earning executive at Crinetics Pharmaceuticals is Dr. R. Scott Struthers Ph.D., Founder, President, CEO & Director, who commands a salary of $978,340.00 per year. Learn More on Alan Seth Krasner's salary.

How do I contact Alan Seth Krasner?

The corporate mailing address for Dr. Krasner and other Crinetics Pharmaceuticals executives is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. Crinetics Pharmaceuticals can also be reached via phone at (858) 450-6464 and via email at [email protected]. Learn More on Alan Seth Krasner's contact information.

Has Alan Seth Krasner been buying or selling shares of Crinetics Pharmaceuticals?

Alan Seth Krasner has not been actively trading shares of Crinetics Pharmaceuticals during the last quarter. Most recently, Alan Seth Krasner sold 7,000 shares of the business's stock in a transaction on Tuesday, October 17th. The shares were sold at an average price of $30.00, for a transaction totalling $210,000.00. Following the completion of the sale, the insider now directly owns 43,210 shares of the company's stock, valued at $1,296,300. Learn More on Alan Seth Krasner's trading history.

Who are Crinetics Pharmaceuticals' active insiders?

Crinetics Pharmaceuticals' insider roster includes Stephen Betz (Insider), Matthew Fust (Director), James Hassard (Chief Commercial Officer), Jeff Knight (COO), Alan Krasner (Chief Endocrinologist), Ajay Madan (Insider), Stephanie Okey (Director), Dana Pizzuti (Chief Medical and Development Officer), Richard Struthers (CEO), and Marc Wilson (CFO). Learn More on Crinetics Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Crinetics Pharmaceuticals?

During the last year, insiders at the sold shares 33 times. They sold a total of 554,549 shares worth more than $26,112,214.05. The most recent insider tranaction occured on November, 22nd when COO Jeff E Knight sold 501 shares worth more than $28,316.52. Insiders at Crinetics Pharmaceuticals own 6.0% of the company. Learn More about insider trades at Crinetics Pharmaceuticals.

Information on this page was last updated on 11/22/2024.

Alan Seth Krasner Insider Trading History at Crinetics Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/17/2023Sell7,000$30.00$210,000.0043,210View SEC Filing Icon  
7/20/2018Buy2,000$17.00$34,000.00View SEC Filing Icon  
See Full Table

Alan Seth Krasner Buying and Selling Activity at Crinetics Pharmaceuticals

This chart shows Alan Seth Krasner's buying and selling at Crinetics Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Crinetics Pharmaceuticals Company Overview

Crinetics Pharmaceuticals logo
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $53.60
Low: $51.73
High: $54.25

50 Day Range

MA: $57.04
Low: $52.09
High: $60.69

2 Week Range

Now: $53.60
Low: $33.67
High: $62.53

Volume

1,940,449 shs

Average Volume

780,930 shs

Market Capitalization

$4.97 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.6